Wednesday, October 28, 2026
Data from SEC filings, checked daily
Public filings, plainly told
WallStPal · PDF guide
PHVS Insider Trading: Pharvaris N.V. Insider Buys and Sells · https://wallstpal.com/stock/phvs/insider-trading/ · saved 2026-10-28

About this page

Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.

How to read it

Form 4
The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
Buy (P) and Sell (S)
Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
Value
Shares times price, as reported on the filing.
10b5-1
A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
Late filing
A Form 4 filed more than two business days after the trade.
Vs. S&P 500
How the stock did after the trade minus how the overall market did in the same weeks.

A real example

In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.

Explain it like I'm 13

If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.

Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.

Summarize with AIChatGPTClaudePerplexityGoogle AIGrokCopilot
Insider tradingForm 4

Pharvaris N.V. (PHVS) Insider Trading

32 open-market trades reported since Jun 17, 2026: 0 purchases worth $0 and 32 sales worth $25.9M.

By insider

InsiderRoleBuysBoughtSellsSoldLatest
Viviane MongesDirector0$01$396KSep 25, 2026
Schikan Johannes Gerardus Christiaan PetrusDirector0$05$8.44MSep 24, 2026
David W. NassifCFO0$01$219KSep 23, 2026
Peng LuPresident0$06$5.74MSep 21, 2026
Elisabeth BjorkDirector0$01$1.99MSep 21, 2026
Anne LesageChief Early Development0$08$4.77MSep 21, 2026
Robert GlassmanDirector0$03$1.19MSep 21, 2026
Stefan Andreas AbeleChief Technical Ops Officer0$01$1.77MSep 17, 2026
Wim SouverijnsChief Commercial Officer0$02$1.02MSep 16, 2026
Berndt ModigCEO0$04$321KSep 15, 2026

All trades

PHVS insider trades
FiledTradedInsiderRoleTypeSharesPrice ($)ValueHolding3 mo. afterFiling
Sep 25Sep 23Viviane MongesDirectorDirector▼ SELL11,96933.05$396K−69%Form 4 ↗
Sep 24Sep 22Schikan Johannes Gerardus Christiaan PetrusDirectorDirector▼ SELL80036.19$29K−0.7%Form 4 ↗
Sep 23Sep 21David W. NassifCFOCFO▼ SELL6,00036.47$219K−5.0%Form 4 ↗
Sep 21Sep 17Schikan Johannes Gerardus Christiaan PetrusDirectorDirector▼ SELL200,00035.00$7.00M−64%Form 4 ↗
Sep 21Sep 17Peng LuPresidentPresident▼ SELL100,00035.00$3.50M−61%Form 4 ↗
Sep 21Sep 17Elisabeth BjorkDirectorDirector▼ SELL52,50037.89$1.99M−78%Form 4 ↗
Sep 21Sep 17Anne LesageChief Early DevelopmentChief Early Development (ind.)▼ SELL20,00038.27$765K−21%Form 4 ↗
Sep 21Sep 17Robert GlassmanDirectorDirector▼ SELL14,49338.56$559K−58%Form 4 ↗
Sep 17Sep 15Stefan Andreas AbeleChief Technical Ops OfficerChief Technical Ops Officer▼ SELL46,40038.17$1.77M−54%Form 4 ↗
Sep 17Sep 15Robert GlassmanDirectorDirector▼ SELL10b5-18,66738.27$332K−45%Form 4 ↗
Sep 16Sep 14Wim SouverijnsChief Commercial OfficerChief Commercial Officer▼ SELL10b5-120,00039.31$786K−31%Form 4 ↗
Sep 16Sep 15Wim SouverijnsChief Commercial OfficerChief Commercial Officer▼ SELL10b5-16,09038.99$237K−14%Form 4 ↗
Sep 15Sep 11Peng LuPresidentPresident▼ SELL10b5-115,00040.13$602K−19%Form 4 ↗
Sep 15Sep 14Berndt ModigCEOCEO▼ SELL10b5-12,29139.40$90K−1.8%Form 4 ↗
Sep 14Sep 10Anne LesageChief Early DevelopmentChief Early Development▼ SELL10b5-130,00038.30$1.15M−35%Form 4 ↗
Sep 11Sep 9Robert GlassmanDirectorDirector▼ SELL10b5-18,00037.55$300K−43%Form 4 ↗
Sep 9Sep 8Peng LuPresidentPresident▼ SELL10b5-115,00040.68$610K−19%Form 4 ↗
Aug 18Aug 14Berndt ModigCEOCEO▼ SELL10b5-12,29234.77$80K−1.7%Form 4 ↗
Jul 15Jul 13Berndt ModigCEOCEO▼ SELL10b5-12,29234.97$80K−1.7%Form 4 ↗
Jul 1Jun 30Schikan Johannes Gerardus Christiaan PetrusDirectorDirector▼ SELL10b5-130,71235.49$1.09M−8.9%Form 4 ↗
Jul 1Jun 30Anne LesageChief Early DevelopmentChief Early Development (ind.)▼ SELL10b5-130,70335.49$1.09M−25%Form 4 ↗
Jul 1Jun 30Anne LesageChief Early DevelopmentChief Early Development▼ SELL10b5-127,87235.48$989K−32%Form 4 ↗
Jul 1Jun 29Anne LesageChief Early DevelopmentChief Early Development▼ SELL10b5-110,60035.07$372K−15%Form 4 ↗
Jul 1Jun 29Anne LesageChief Early DevelopmentChief Early Development (ind.)▼ SELL10b5-16,99735.05$245K−5.3%Form 4 ↗
Jul 1Jun 29Schikan Johannes Gerardus Christiaan PetrusDirectorDirector▼ SELL10b5-16,88835.05$241K−2.0%Form 4 ↗
Jun 29Jun 25Peng LuChief Medical OfficerChief Medical Officer▼ SELL10b5-115,00034.60$519K−19%Form 4 ↗
Jun 29Jun 26Peng LuChief Medical OfficerChief Medical Officer▼ SELL10b5-114,70034.00$500K−18%Form 4 ↗
Jun 29Jun 29Schikan Johannes Gerardus Christiaan PetrusDirectorDirector▼ SELL10b5-12,40035.10$84K−0.7%Form 4 ↗
Jun 29Jun 25Anne LesageChief Early DevelopmentChief Early Development (ind.)▼ SELL10b5-12,30035.12$81K−1.7%Form 4 ↗
Jun 29Jun 25Anne LesageChief Early DevelopmentChief Early Development▼ SELL10b5-12,30035.12$81K−3.9%Form 4 ↗
Jun 23Jun 18Peng LuChief Medical OfficerChief Medical Officer▼ SELL10b5-130034.00$10K−0.5%Form 4 ↗
Jun 17Jun 15Berndt ModigCEOCEO▼ SELL10b5-12,29131.07$71K−1.7%Form 4 ↗
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings